Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Shanghai Xunbaihui Biotechnology Co. Ltd. maintains 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners but remain contained within 1 distinct art unit, suggesting consistent examination standards across the portfolio. This structure indicates that while the company is engaging with multiple examiners, the technical focus remains consistent within a single specialized department of the patent office.
TAYLOR, LIA ELAN serves as the busiest examiner for the portfolio with 1 busiest examiner pending action. While there are 2 pending office actions total, the workload is split between the 2 distinct examiners, requiring the applicant to manage separate examiner interactions within 1 distinct art unit. This dual-examiner approach within a single unit may offer insights into how different individuals interpret the same technical standards, providing a broader perspective on the unit's overall examination trends for biotechnology filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TAYLOR, LIA ELAN | 1 | 64.4% | +29.4% |
| PETRASH, HILARY ANN | 1 | 64.5% | +51.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18020447 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS BY TARGETING IGSF8 | PETRASH, HILARY ANN | 27d |
| 18682489 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS BY TARGETING IGSF8 | TAYLOR, LIA ELAN | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682489 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS BY TARGETING IGSF8 | TAYLOR, LIA ELAN | — | §112DP | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18020447 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS BY TARGETING IGSF8 | PETRASH, HILARY ANN | 1644 | §112 | Final Rejection | 27d | Pending | Feb 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial